SEC Form SC 13G filed by MacroGenics Inc.

SEC Form SC 13G filed by MacroGenics Inc.

Recent Analyst Ratings for $MGNX

$MGNX Insider Purchases

$MGNX Insider Trading

$MGNX Large Ownership Changes

$MGNX Press Releases

$MGNX SEC Filings

$MGNX Leadership Updates

$MGNX Analyst Ratings

$MGNX Financials

$MGNX FDA approvals

Recent Analyst Ratings for
$MGNX

$MGNX
Insider Purchases

$MGNX
Insider Trading

$MGNX
Large Ownership Changes

$MGNX
Press Releases

$MGNX
SEC Filings

$MGNX
Leadership Updates

$MGNX
Analyst Ratings

$MGNX
Financials

$MGNX
FDA approvals

Chat with this insight

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Biotech Target N V bought $669,585 worth of shares (150,000 units at $4.46), increasing direct ownership by 2% to 9,929,963 units (SEC Form 4)

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Sr VP, Research & CSO Bonvini Ezio converted options into 16,665 shares, increasing direct ownership by 15% to 124,414 units (SEC Form 4)

SVP, CFO and Secretary Karrels James converted options into 14,998 shares and covered exercise/tax liability with 5,790 shares (SEC Form 4)

President and CEO Koenig Scott converted options into 42,329 shares, increasing direct ownership by 6% to 777,415 units (SEC Form 4)

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by MacroGenics Inc.

Amendment: SEC Form SC 13G/A filed by MacroGenics Inc.

SEC Form SC 13G filed by MacroGenics Inc.

Fastest customizable press release news feed in the world

MacroGenics Announces Date of First Quarter 2025 Financial Results

MacroGenics to Participate in Upcoming Investor Conference

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

SEC Form DEFA14A filed by MacroGenics Inc.

SEC Form DEF 14A filed by MacroGenics Inc.

MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Live Leadership Updates

MacroGenics Announces Leadership Transition

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

MacroGenics Announces Appointment of William Heiden to Board of Directors

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

MacroGenics downgraded by JMP Securities

MacroGenics downgraded by BTIG Research

MacroGenics downgraded by B. Riley Securities with a new price target

Live finance-specific insights

MacroGenics Announces Date of First Quarter 2025 Financial Results

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for MARGENZA issued to MACROGENICS INC

FDA Approval for MARGENZA

11/20/24 10:44:27 AM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MGNX alert in real time by email

SC 13G 1 d881560dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. __)*

MacroGenics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

556099109

(CUSIP Number)

November 14, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 556099109

(1)

Consists of 1,549,193 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

Consists of 925,809 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

Consists of 125,513 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

Consists of 575,150 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

Consists of (i) 1,549,193 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 925,809 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 125,513 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iv) 575,150 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

Consists of (i) 1,549,193 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 925,809 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.

CUSIP No. 556099109

(1)

(2)	Based on 62,763,448 shares of Common Stock outstanding on November 1, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on November 5, 2024.


Item 1(a).		Name of Issuer: MacroGenics, Inc.

Item 1(b).		Address of Issuer’s Principal Executive Offices: 9704 Medical Center Drive, Rockville, MD 20850

Item 2(a).		Name of Person Filing: The entities and persons filing this statement (collectively, the “Reporting Persons”) are: Frazier Life Sciences Public Fund, L.P. (“FLSPF”) FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences Public Overage Fund, L.P. (“FLSPOF”) FHMLSP Overage, L.P. FHMLSP Overage, L.L.C. Frazier Life Sciences XI, L.P. (“FLS XI”) FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences X, L.P. (“FLS X”) FHMLS X, L.P. FHMLS X, L.L.C. James N. Topper (“Topper”) Patrick J. Heron (“Heron”) Albert Cha (“Cha”) James Brush (“Brush”) Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).		Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite B Palo Alto, CA 94304


Item 2(c).	Citizenship:

	Entities:	FLSPF	-	Delaware, U.S.A.
		FHMLSP, L.P.	-	Delaware, U.S.A.
		FHMLSP, L.L.C.	-	Delaware, U.S.A.
		FLSPOF	-	Delaware, U.S.A.
		FHMLSP Overage, L.P.	-	Delaware, U.S.A.
		FHMLSP, L.L.C.	-	Delaware, U.S.A.
		FLS XI	-	Delaware, U.S.A.
		FHMLS XI, L.P.	-	Delaware, U.S.A.
		FHMLS XI, L.L.C.	-	Delaware, U.S.A.
		FLS X	-	Delaware, U.S.A.
		FHMLS X, L.P.	-	Delaware, U.S.A.
		FHMLS X, L.L.C.	-	Delaware, U.S.A.

	Individuals:	Topper	-	United States Citizen
		Heron	-	United States Citizen
		Cha	-	United States Citizen
		Brush	-	United States Citizen
		Estes	-	United States Citizen


Item 2(d).		Title of Class of Securities: Common Stock

Item 2(e).		CUSIP Number: 556099109

Item 3.		If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

(a)		☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)		☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);


(c)		☐ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)		☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)		☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)		☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)		☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)		☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)		☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)		☐ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)		☐ Group, in accordance with §240.13d–1(b)(1)(ii)(K).

		If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: November 20, 2024	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
	By: FHMLSP, L.P., its General Partner
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	FHMLSP, L.P.
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	FHMLSP, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.
	By: FHMLSP Overage, L.P., its General Partner
	By: FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	FHMLSP OVERAGE, L.P.
	By FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	FHMLSP OVERAGE, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	FRAZIER LIFE SCIENCES XI, L.P.
	By: FHMLS XI, L.P., its General Partner
	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	FHMLS XI, L.P.
	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer


Date: November 20, 2024	FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	FRAZIER LIFE SCIENCES X, L.P.
	By: FHMLS X, L.P., its General Partner
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	FHMLS X, L.P.
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 20, 2024	By:	*
		James N. Topper

Date: November 20, 2024	By:	*
		Patrick J. Heron

Date: November 20, 2024	By:	**
		Albert Cha

Date: November 20, 2024	By:	**
		James Brush

Date: November 20, 2024	By:	***
		Daniel Estes

Date: November 20, 2024	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

Exhibit Index


Exhibit A -		Agreement regarding filing of joint Schedule 13G.

Get the next $MGNX alert in real time by email

Date	Price Target	Rating	Analyst
11/7/2024		Mkt Outperform → Mkt Perform	JMP Securities
8/1/2024		Buy → Neutral	BTIG Research
7/31/2024	$18.00 → $5.00	Buy → Neutral	B. Riley Securities
7/31/2024		Buy → Neutral	Guggenheim
5/10/2024	$24.00 → $8.00	Outperform → Market Perform	BMO Capital Markets
5/10/2024	$29.00 → $7.00	Buy → Hold	Stifel
5/10/2024		Buy → Hold	TD Cowen
4/26/2024	$25.00	Buy	B. Riley Securities

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware